Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors
European Journal of Nuclear Medicine and Molecular Imaging · 2025-03 · 52 (4) · 1305-1320
DOI: 10.1007/s00259-024-07011-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 04.12.2024. Verfasst von Fabrice N Njotu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Neuroendocrine Tumors, Pancreatic Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Molecular Targeting Technologies Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
- Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5A2, Canada.
- Axe Oncologie, Centre de Recherche du CHU de Québec-Université Laval, 2250 Boul. Henri-Bourassa, Québec, QC, G1J 5B3, Canada.
- Faculté de Pharmacie, Université Laval, Ferdinand Andry Pavillon, 1050 Av. de la Medicine, Québec, QC, G1V 0A6, Canada.
- Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, S7N 5B4, Canada.
- Molecular Targeting Technologies, Inc. West Chester, West Chester, PA, 19380, USA.
ORCID-Profile: Humphrey Fonge
Förderung
- Molecular Targeting Technologies Inc
Zitieren
APA
Njotu, F. N., Pougoue Ketchemen, J., Babeker, H., Henning, N., Tikum, A. F., Nwangele, E., Monzer, A., Hassani, N., Gray, B. D., Pak, K. Y., Torlakovic, E. E., Uppalapati, M., & Fonge, H. (2025). Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 52(4), 1305-1320. https://doi.org/10.1007/s00259-024-07011-2
Vancouver
Njotu FN, Pougoue Ketchemen J, Babeker H, Henning N, Tikum AF, Nwangele E, et al. Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(4):1305-1320. doi:10.1007/s00259-024-07011-2
BibTeX
@article{Njotu2025,
author = {Njotu, Fabrice N and Pougoue Ketchemen, Jessica and Babeker, Hanan and Henning, Nikita and Tikum, Anjong F and Nwangele, Emmanuel and Monzer, Alissar and Hassani, Nava and Gray, Brian D and Pak, Koon Y and Torlakovic, Emina E and Uppalapati, Maruti and Fonge, Humphrey},
title = {Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {4},
pages = {1305--1320},
doi = {10.1007/s00259-024-07011-2}
}
EUVIMED